Tumor angiogenesis

By Farah Fatmawati, Whendy Wijaksono. Advances in Cancer Research, 2020

2,509 citations recorded by the source corpus.

The hypothesis that tumors are angiogenesis dependent has, in the past decade, generated new investigations designed to elucidate the mechanism of angiogenesis itself. Many laboratories are now engaged in this pursuit. Some are studying angiogenesis that occurs in physiological situations, whereas others are interested in angiogenesis that dominates pathological conditions. These efforts have led to (1) the development of bioassays for angiogenesis; (2) the partial purification and, in one case, the complete purification of angiogenic factors from neoplastic and non-neoplastic cells; (3) the development of new polymer technology for the sustained release of these factors and other macromolecules in vivo; (4) the cloning and long-term culture of capillary endothelial cells; (5) the demonstration of the role of nonendothelial cells, such as mast cells in modulating angiogenesis; (6) the discovery of angiogenesis inhibitors; and (7) the demonstration that certain animal tumors will regress when angiogenesis is inhibited. The effects of angiogenesis inhibitors provide perhaps the most compelling evidence for the role of angiogenesis in tumor growth. It is conceivable that the original effort to understand the role of angiogenesis in tumor growth will also lead to the use of angiogenesis inhibitors as a new class of pharmacologic agents in a variety of non-neoplastic diseases such as arthritis, psoriasis, and ocular neovascularization. However, much work remains to be done before it will be possible to understand (1) the regulatory systems that govern capillary density in normal tissues; (2) the factors that maintain the viability of microvascular endothelium; (3) the development of the vascular system itself; and (4) the mechanism by which vascular regression occurs, both in the embryo and in the postnatal organism. A knowledge of the mechanisms which underlie these normal processes may help to enlarge our comprehension of tumor angiogenesis.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/23c86ac7d3e450caae1144af8ab6effd7ef34c01

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Rakesh K. Jain
2. N. Ferrara
3. D. Hanahan
4. Dai Fukumura
5. A. Adamis
6. R. Weinberg
7. G. Bergers
8. R. Roskoski

Citations in the corpus

• Long-circulating and target-specific nanoparticles: theory to practice. (2001, neutral): “To meet the metabolic requirements of the expanding population of tumor cells, the pre-existing blood vessels become subject to intense angiogenic pressure (Folkman, 1995).”
• The role of pericytes in blood-vessel formation and maintenance. (2005, background): “Because of the imbalanced expression pattern of angiogenic factors, tumor vessels appear to be in a constant state of remodeling, which involves simultaneous formation and regression of vascular tubes (Bergers and Benjamin, 2003; Folkman, 2000).”
• The therapeutic promise of the cancer stem cell concept. (2010, background): “Indeed, despite great promise, conventional VEGF-targeted therapies have shown an unexpectedly limited survival benefit in the clinic (68), and this had led to additional studies aimed at further dissecting the effects of VEGF inhibition on primary tumor growth and tumor metastatic potential.”
• Targeting PI3K/Akt signal transduction for cancer therapy (2021, background): “Multiple signaling pathways have been shown to be involved in the regulation of tumor angiogenesis, among which PI3K/Akt signaling is the most important.(159) PI3K forms a complex with E-cadherin, β-catenin, and VEGFR-2 and is involved in endothelial signaling mediated by VEGF through the activation”
• Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. (2001, background): “These include uncontrolled cell growth attributable to the autocrine production of growth factors by cancer cells and stimulation of tumor neovascularization as a result of paracrine stimulation of normal endothelial cells by angiogenic growth factors secreted by cancer cells (1, 2).”
• Basic and therapeutic aspects of angiogenesis. (2011, neutral): “Role of Myeloid Cells in Tumor Vessel Vascularization Various hematopoietic lineages influence tumor angiogenesis (Kerbel, 2008).”
• Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. (2005, background): “Angiogenesis also plays a pivotal role in several pathologic disorders, particularly tumorigenesis and metastases (6).”
• Vascular endothelial growth factor (VEGF) signaling in tumor progression. (2007, background): “hese endothelial cells correspond to an estimated surface rea of 1000 m2, about the size of a tennis court [8].”
• DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. (2001, background): “We conclude that the nontumor DNA in human plasma originates from other cells surrounding the tumor tissue that are degenerated by the growing tumor (38).”
• Nanomedicine in cancer therapy (2023, background): “49,88 It has been shown that VEGF 121 - conjugated mesoporous silica nanoparticle could selectively deliver sunitinib, a potent receptor tyrosine kinase inhibitor, to tumor blood vessels in human U87MG glioblastoma-bearing mice by targeting VEGFR2, and exhibited superior anti-tumor ef fi cacy…”
• A history of the study of solid tumour growth: The contribution of mathematical modelling (2004, background): “Theseminal work on tumour angiogenesis by Folkman(1974) arosefrom the discovery of dormant avascular tumour nodules in vivo. Greene(1961) had observed that the growth of tumour fragments implanted in the anterior chamber of the guinea pig eye ceased because of their inability to acquire a vasculatur”
• Diabetes and Wound Angiogenesis (2017, background): “Pathological angiogenesis is most often associated with malignancy, where excessive angiogenesis can continue without order or end as tumor growth [34].”
• Obesity and Cancer: The Role of Dysfunctional Adipose Tissue (2009, background): “Because VEGF plays an important role in tumor angiogenesis (147), increased levels of this key endothelial mitogen may contribute to the poorer outcome of cancer in obese subjects.”
• Oxidative stress, inflammation, and cancer: how are they linked? (2010, background): “vessels to form a new vascular network for the supply of nutrients and oxygen [217].”